Guardant Health is experiencing accelerating revenue growth, with Q2 2026 revenue up 44.3% year-over-year to $335.0M, driven by strong adoption of its liquid biopsy tests.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth accelerated to 44.3% year-over-year in Q2 2026, reaching $335.0M, while gross margin improved to 65.4%, but operating margin remained deeply negative at -38.5%.
Guardant Health's Shield blood test was added to the American Cancer Society's colorectal cancer screening guidelines, enhancing its market potential for average-risk adults.
The FDA approved Guardant360 CDx as a companion diagnostic for VEPPANU, enabling blood-based detection of ESR1 mutations in ER-positive breast cancer.
Guardant's InfinityAI and Guardant360 platforms provided real-world evidence supporting Japan's approval of ENHERTU for HER2-positive solid tumors, showcasing its clinical utility.
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | -$0.29+61.3% vs -$0.75 | $361M+2.9% vs $351M |
Q3 2026 Jul 30, 2026 | -$0.90-18.1% vs -$0.76 | $335M+6.6% vs $314M |
Q2 2026 May 7, 2026 | -$0.85-5.5% vs -$0.81 | $302M+8.1% vs $279M |
Q1 2026 Feb 19, 2026 | -$1.00-30.4% vs -$0.77 | $281M+3.2% vs $272M |
Guardant Health NASDAQ: GH raised its full-year 2026 revenue forecast after third-quarter sales increased 36%, driven by growth in its oncology testing business and demand for its Shield blood-based cancer screening test.
Guardant Health (GH) came out with a quarterly loss of $0.29 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.39 per share a year ago.
The headline numbers for Guardant Health (GH) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended September 30, 2026. Third Quarter 2026 Financial Highlights For the three-month period ended September 30, 2026, as compared to the same period of 2025: Reported total revenue of $361.0 million, an increase of 36%, driven by: Oncology revenue of $231.3 million, an increase of 25%, and 117,000 oncology tests, an increase of 58% Bioph.
Benchmark GH against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Guardant Health, Inc. (GH)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $150.87 | $20.01B | -41.81 | 32.88% | -37.93% | — | — | |
| $213.13 | $32.25B | 36.67 | -0.78% | 19.72% | 31.45% | — | |
| $310.67 | $44.49B | -271.73 | 35.9% | -5.66% | -9.18% | — | |
| $12.25 | $640.38M | -4.80 | — | -194.74% | -41.33% | — | |
| $1.96 | $185.32M | 5.27 | 161.14% | 47.55% | 42.57% | — | |
| $2.26 | $701.96M | -5.36 | 3.89% | -81.31% | -2618.51% | — |
Guardant Health, Inc. (GH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Guardant Health, Inc. (GH) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 30, 2026·SEC
Jun 18, 2026·SEC
May 7, 2026·SEC
Feb 19, 2026·SEC
Get notified when GH posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Guardant Health, Inc. (GH) stock FAQ — growth, dividends, profitability & financials explained
Guardant Health, Inc. (GH) reported $1.28B in revenue over the trailing twelve months. Revenue was $982.0M in fiscal year 2025. That is 3789% more than the $25.2M of fiscal year 2016.
Guardant Health, Inc. (GH) grew revenue by 41.7% over the trailing twelve months, compared with the twelve months before.
No. Guardant Health, Inc. (GH) reported a net loss of $485.1M over the trailing twelve months.
Guardant Health, Inc. (GH) had negative free cash flow of $232.1M over the trailing twelve months.
